Comparing Ticagrelor Alone Versus Aspirin and Clopidogrel After PCI in Chronic Coronary Syndrome Patients
A 6-Month Randomized Study at a Single Center
Led by Shiraz University of Medical Sciences · Updated on 2025-05-21
5400
Participants Needed
2
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of two antiplatelet treatments for patients with chronic coronary syndrome who undergo percutaneous coronary intervention PCI using drug-eluting stents. The trial compares ticagrelor alone against the standard dual therapy of aspirin and clopidogrel. The study aims to measure major adverse cardiovascular events MACE, including cardiac death, myocardial infarction, stent thrombosis, and the need for further revascularization within six months after PCI.
Patients will be randomly assigned to one of two groups after diagnostic angiography but before stent placement. One group will receive conventional dual antiplatelet therapy consisting of aspirin 80 mg once daily and clopidogrel 75 mg once daily. The other group will receive ticagrelor monotherapy at 90 mg twice daily. Treatment will begin with a loading dose before stent insertion unless patients are already on maintenance therapy. The intervention period lasts for six months.
Participants will be monitored throughout the study for cardiovascular events, bleeding, and adverse treatment reactions. The study includes detailed safety assessments, and outcomes such as stent thrombosis and MACE will be tracked for six months post-PCI. The trial uses a randomized, triple-blind design and involves follow-up within a registry at a cardiology clinic. The total participation time covers the initial procedure and six months of treatment and monitoring.
CONDITIONS
Brief Title
Ticagrelore Alone Post PCI
Research Team
J
javad UOM Kojuri, MD.MS
J
javad UOM Kojuri, MD.MS.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Male or female above 20 years of age undergoing PCI with a drug-eluting stent for chronic coronary syndrome
Provided written informed consent approved by the ethics committee of Shiraz University of Medical Sciences
You will not qualify if you...
Allergy or contraindication to aspirin, clopidogrel, ticagrelor, or other reason to avoid these drugs (including hypersensitivity, moderate or severe liver disease, active bleeding, major surgery within 30 days)
Atrial fibrillation or other reason for oral anticoagulant therapy
Concurrent oral or IV therapy with strong CYP3A inhibitors, certain CYP3A substrates, or strong CYP3A inducers
Females of childbearing age not having a negative pregnancy test or unwilling to use effective contraception during the trial
Breastfeeding females at enrollment
Unsuccessful PCI or PCI without optimal stent placement
Anatomical SYNTAX score 23 or higher prior to PCI
Planned surgical intervention for cardiac or non-cardiac condition
Previous PCI in the last 6 months
Current or recent (within 12 months) acute coronary syndrome
History of stent thrombosis
Cardiac valve disease requiring invasive therapy
Acute heart failure
Active myocarditis
Cardiomyopathy
Hemodialysis
History of stroke or transient ischemic attack
History of intracranial hemorrhage or other brain conditions increasing bleeding risk
Hemoglobin less than 10 g/dL
Recent peptic ulceration unless healed
Any condition causing excessive bleeding risk with ticagrelor
Participation in another investigational drug or device trial
Unlikely to comply with study procedures or follow-up
Known drug or alcohol dependence within past 12 months
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessment
Treatment
Duration - 6 months
Participants undergo percutaneous coronary intervention (PCI) followed by assigned antiplatelet therapy with either ticagrelor alone or dual antiplatelet therapy for six months.
Regular visits during the 6-month treatment period for monitoring and medication management
Follow-up
Duration - Up to 6 months after treatment
Participants are monitored for safety and efficacy outcomes including cardiac events and bleeding after completing the 6-month treatment period.
Visits scheduled as needed for safety and efficacy assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Comparing 24-Month Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent Placement in Patients With High Lipoproteina Levels
Evaluation of a 10-Minute Cardiovascular Magnetic Resonance Protocol for Diagnosing Cardiac Diseases Including Coronary Artery Disease and Cardiomyopathies
Study of Implantable Cardioverter Defibrillator Benefits in Adults with Coronary Artery Disease and Ventricular Fibrillation After Complete Revascularization
Randomized Double-Blind Study Evaluating Intravenous YN001 Versus Placebo in Adults With Coronary Atherosclerosis Receiving Cardiovascular Risk Therapy
Validating the ABCD-GENE Score to Identify Stable Coronary Artery Disease Patients Undergoing Elective PCI at Risk of Heart Injury During Procedure
Real-World Registry of Quantitative Flow Ratio-Guided Coronary Revascularization and Quality Evaluation Across Multiple Centers in China
Evaluating Coronary CT Angiography to Guide Calcium Modification Compared to Intravascular Ultrasound in Treating Calcified Coronary Artery Disease A Multicenter Randomized Trial
Study on Ultrasound Screening and Combined Treatments for Patients With Coronary and Head and Neck Artery Narrowing
Study of Yiyang Huoluo Decoction Combined with Western Medicine to Treat Coronary Heart Disease and Atherosclerosis in Older Adults
Evaluating Pre-Procedural Intracoronary Nicorandil to Prevent Reduced TIMI Flow in Patients Undergoing Percutaneous Coronary Intervention for Coronary Artery Disease
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Rationale and design of randomized non-inferiority clinical trial to compare the safety and efficacy of ticagrelor monotherapy with dual antiplatelet therapy in chronic coronary syndrome patients post percutaneous coronary intervention (TICALONE-TAHA10 Protocol).